• Injection Sites & Technique: Target the lip body, vermillion border, and philtrum columns, tailoring the technique to the patient’s individual anatomy and aesthetic goals.
• Anesthesia: Additional topical anesthesia is optional, as 0.3% lidocaine is already co-formulated within the gel to minimize discomfort.
• Vascular Safety: Maintain strict aseptic technique and pay close attention to perioral vascular anatomy to prevent intravascular injection.
• Volume Control: Avoid overcorrection and excessive product placement in high-mobility lip tissue.
• Patient Aftercare: Advise patients to avoid sun exposure, extreme heat, alcohol, and strenuous activity until redness, swelling, or tenderness resolves.
• Clinical Risks: Monitor for severe complications, including vascular occlusion, skin necrosis, and visual disturbances, as well as typical localized side effects like transient bruising and swelling.

• Indicated for lip augmentation, including volume enhancement, lip border definition, and correction of lip volume loss.
• Indicated for the perioral treatment area, including the vermillion border, philtrum columns, and perioral lines, depending on local labeling and clinical assessment.
• Designed for pronounced augmentation and patients with significant volume loss or those requiring more defined lip shaping.
• Prescribed for administration by licensed aesthetic medicine professionals only and is not intended for self-administration.

Product Specifications

• Active ingredient: Cross-linked hyaluronic acid 20 mg/mL, 0.3% lidocaine, and 0.9% mannitol.
• Format: Injectable gel supplied in 1 × 1 mL prefilled syringe with 2 × 30G ½ needles.
• Manufacturer: Laboratoires VIVACY, France.
• Drug class: Injectable cross-linked hyaluronic acid filler for lip augmentation, formulated with lidocaine.
• Technology: IPN-Like Technology™; BI-FLEX® rheological profile adapted to lip tissue dynamics.
• Regulatory status: CE-marked for EU use; US FDA status should be verified by jurisdiction before procurement.

Contraindications

• Do not administer to patients with known hypersensitivity to hyaluronic acid, lidocaine, amide-type anesthetics, or any excipient in the formulation.
• Do not inject into areas with active skin infection, inflammation, open lesions, or active perioral conditions such as herpes labialis.
• Avoid use during pregnancy or breastfeeding as a precaution, due to limited safety data in these populations.

• Inject into lip tissue only; target the lip body, vermillion border, and philtrum, with depth and placement matched to lip anatomy and the degree of volume loss.
• Topical anesthesia is optional, as 0.3% lidocaine is already co-formulated in the gel.
• Allow the syringe to reach room temperature before administration to support smoother gel flow.
• The product is intended for single use only; discard any unused gel, syringe, and needle after the procedure.
• Screen for hypersensitivity to hyaluronic acid and amide-type anesthetics before treatment and refer to the full IFU.

Legal & Regulatory Status

STYLAGE® LIPS PLUS BI-FLEX® with Lidocaine is a CE-marked medical device manufactured by Laboratoires VIVACY (France). Its regulatory status in other jurisdictions, including the United States, should be verified before procurement. Practitioners who wish to buy dermal fillers or buy STYLAGE® may contact the Med Supply Solutions support team for sourcing information and documentation support.

1. Stéphane S, Candice SM, Florence B. “Bi-Bi” technique for lip augmentation: A retrospective study on 30 cases. J Cosmet Dermatol. 2022;21(10):4339-4344. doi:10.1111/jocd.15221
2. Ramos-E-Silva M, Fonteles LA, Lagalhard CS, Fucci-da-Costa AP. STYLAGE®: a range of hyaluronic acid dermal fillers containing mannitol. Physical properties and review of the literature. Clin Cosmet Investig Dermatol. 2013;6:257-261. Published 2013 Oct 23. doi:10.2147/CCID.S35251

The contents of this page are meant for licensed medical professionals. They serve informational purposes only and are not to be taken as medical advice.